Status: Recruiting
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma. This is a randomized and open-label study, with two dose groups set up, and 10 to 20 subjects will be enrolled in each group.
Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.Updated: Jul 9, 2025Locations: 1
Eligibility criteria
Voluntarily sign the informed consent form; [+10]
Having been previously exposed to any anti-TIGIT, PD-1, PD-L1 or CTLA-4 drugs; [+17]